| Literature DB >> 27312374 |
Barbara B Maier1,2, Anastasiya Hladik2, Karin Lakovits2, Ana Korosec1,2, Rui Martins1,2, Julia B Kral3, Ildiko Mesteri4, Birgit Strobl5, Mathias Müller5, Ulrich Kalinke6,7, Miriam Merad8, Sylvia Knapp9,10.
Abstract
Protecting the integrity of the lung epithelial barrier is essential to ensure respiration and proper oxygenation in patients suffering from various types of lung inflammation. Type I interferon (IFN-I) has been associated with pulmonary epithelial barrier function, however, the mechanisms and involved cell types remain unknown. We aimed to investigate the importance of IFN-I with respect to its epithelial barrier strengthening function to better understand immune-modulating effects in the lung with potential medical implications. Using a mouse model of pneumococcal pneumonia, we revealed that IFN-I selectively protects alveolar epithelial type II cells (AECII) from inflammation-induced cell death. Mechanistically, signaling via the IFN-I receptor on AECII is sufficient to promote AECII survival. The net effects of IFN-I are barrier protection, together with diminished tissue damage, inflammation, and bacterial loads. Importantly, we found that the protective role of IFN-I can also apply to sterile acute lung injury, in which loss of IFN-I signaling leads to a significant reduction in barrier function caused by AECII cell death. Our data suggest that IFN-I is an important mediator in lung inflammation that plays a protective role by antagonizing inflammation-associated cell obstruction, thereby strengthening the integrity of the epithelial barrier.Entities:
Keywords: Acute lung injury; Alveolar epithelial cells; Epithelial barrier; Pneumococcal pneumonia; Type I interferon
Mesh:
Substances:
Year: 2016 PMID: 27312374 PMCID: PMC5370074 DOI: 10.1002/eji.201546201
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532